Dan Edelstein, Haystack Oncology CEO

Fol­low­ing AS­CO show­ing, Bert Vo­gel­stein’s lat­est start­up launch­es in­to re­cur­rent can­cer de­tec­tion

Can­cer re­search lu­mi­nary Bert Vo­gel­stein is adding to his line of can­cer di­ag­nos­tic com­pa­nies, fol­low­ing Ex­act Sci­ences, In­os­tics, PGDx and Thrive (which was bought by Ex­act).

Haystack On­col­o­gy is launch­ing out of Catalio Cap­i­tal Man­age­ment, where Vo­gel­stein serves as a ven­ture part­ner as well. It’s start­ing out with a $56 mil­lion Se­ries A, adding to its $10 mil­lion in seed fund­ing, which was led by Catalio but al­so fea­tured re­search tool man­u­fac­tur­er Bruk­er, the ven­ture arm of Ex­act, and Alexan­dria Ven­ture In­vest­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.